Literature DB >> 35689759

Magnetic resonance imaging of methotrexate-related lymphoproliferative disorder with a chief complaint of oral symptoms.

Ami Kuribayashi1, Sakurako Kawashima2, Kou Kayamori3, Junichiro Sakamoto2, Hiroshi Tomisato4, Hiroshi Watanabe2, Tohru Kurabayashi2.   

Abstract

OBJECTIVES: To determine the magnetic resonance imaging (MRI) features of methotrexate-related lymphoproliferative disorder (MTX-LPD) in the oral cavity of a patient with a chief complaint of oral symptoms.
METHODS: We included six patients who visited our hospital between November 2014 and November 2019, histopathologically diagnosed with MTX-LPD. All images were examined using 3 T MRI and reviewed by two radiologists.
RESULTS: Masses were detected in five cases; all masses demonstrated signal hypointensity and homogeneous signal hyperintensity on T1- and T2-weighted images with fat suppression. Homogeneous enhancement with fat suppression was evident on post-contrast T1-weighted imaging. We performed dynamic contrast-enhanced MRI in three cases and observed early enhancement with a low washout ratio pattern in all cases. Four patients underwent diffusion-weighted MRI and revealed low mean apparent diffusion coefficient (ADC) of 0.57 (range 0.5-0.65) × 10-3 mm2/s.
CONCLUSIONS: We reported on the imaging characteristics of six rare cases of MTX-LPD in the oral cavity. Homogeneous hyperintensity on fat-suppressed T2-weighted images and low ADC values are possible features of MTX-LPD. Moreover, MTX-LPD can be differentiated from other carcinomas in the oral cavity.
© 2022. The Author(s) under exclusive licence to Japanese Society for Oral and Maxillofacial Radiology.

Entities:  

Keywords:  MRI; MTX-LPD; Methotrexate-related lymphoproliferative disorder; Oral; Radiology

Year:  2022        PMID: 35689759     DOI: 10.1007/s11282-022-00626-x

Source DB:  PubMed          Journal:  Oral Radiol        ISSN: 0911-6028            Impact factor:   1.852


  21 in total

1.  Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication.

Authors:  Yoshihiko Hoshida; Jing-Xian Xu; Shigeki Fujita; Itsuko Nakamichi; Jun-Ichiro Ikeda; Yasuhiko Tomita; Shin-Ichi Nakatsuka; Jun-Ichi Tamaru; Atsushi Iizuka; Tsutomu Takeuchi; Katsuyuki Aozasa
Journal:  J Rheumatol       Date:  2006-11-15       Impact factor: 4.666

Review 2.  Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.

Authors:  E Salloum; D L Cooper; G Howe; J Lacy; G Tallini; J Crouch; M Schultz; J Murren
Journal:  J Clin Oncol       Date:  1996-06       Impact factor: 44.544

3.  Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population.

Authors:  Atsushi Hashimoto; Noriyuki Chiba; Hirotaka Tsuno; Akiko Komiya; Hiroshi Furukawa; Toshihiro Matsui; Jinju Nishino; Shigeto Tohma
Journal:  J Rheumatol       Date:  2015-01-15       Impact factor: 4.666

4.  Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France.

Authors:  Xavier Mariette; Dominique Cazals-Hatem; Josiane Warszawki; Frédéric Liote; Nathalie Balandraud; Jean Sibilia
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

5.  Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate.

Authors:  M H Ellman; H Hurwitz; C Thomas; M Kozloff
Journal:  J Rheumatol       Date:  1991-11       Impact factor: 4.666

6.  Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein-Barr virus and other features associated with immunosuppression.

Authors:  O W Kamel; M van de Rijn; D P LeBrun; L M Weiss; R A Warnke; R F Dorfman
Journal:  Hum Pathol       Date:  1994-07       Impact factor: 3.466

7.  Methotrexate-related lymphoproliferative disorder arising in the gingiva of a patient with rheumatoid arthritis.

Authors:  N Horie; R Kawano; T Kaneko; T Shimoyama
Journal:  Aust Dent J       Date:  2015-07-24       Impact factor: 2.291

8.  Methotrexate-related Epstein-Barr virus-associated lymphoproliferative disorder occurring in the gingiva of a patient with rheumatoid arthritis.

Authors:  Mitsuaki Ishida; Keiko Hodohara; Miyuki Yoshii; Hiroko Okuno; Akiko Horinouchi; Ryota Nakanishi; Ayumi Harada; Muneo Iwai; Keiko Yoshida; Akiko Kagotani; Takashi Yoshida; Hidetoshi Okabe
Journal:  Int J Clin Exp Pathol       Date:  2013-09-15

Review 9.  Oral Methotrexate-related Lymphoproliferative Disease Presenting with Severe Osteonecrosis of the Jaw: A Case Report and Literature Review.

Authors:  Sachiko Furukawa; Kazunari Oobu; Masafumi Moriyama; Shintaro Kawano; Saori Sako; Jun-Nosuke Hayashida; Ryota Matsubara; Ken-Ichi Ogata; Tamotsu Kiyoshima; Seiji Nakamura
Journal:  Intern Med       Date:  2017-12-08       Impact factor: 1.271

Review 10.  Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?

Authors:  Vasco Crispim Romão; Helena Canhão; João Eurico Fonseca
Journal:  BMC Med       Date:  2013-01-23       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.